The unprecedented demand for GLP-1 receptor agonist medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — combined with frequent drug shortages and high list prices — created a massive market for compounded versions of these medications. Compounding pharmacies began producing semaglutide and tirzepatide preparations at a fraction of the brand-name cost, often marketed aggressively through online platforms and medical spas. While the financial appeal is understandable, the FDA has issued multiple urgent safety warnings about these products. This article explains why compounded GLP-1 RA represents a serious and poorly understood patient safety risk.
What Is Pharmaceutical Compounding?
Pharmaceutical compounding is the practice of preparing a customized medication for an individual patient when a commercially available product does not meet that patient’s specific medical needs — for example, creating a liquid formulation for a patient who cannot swallow pills, or preparing a preservative-free version for allergy reasons. Compounding is legal and valuable in narrow, legitimate clinical contexts.
However, compounding becomes problematic — and potentially illegal — when it is used to produce large-scale copies of commercially available, FDA-approved drugs to circumvent the standard drug approval process. This is precisely what occurred with compounded semaglutide and tirzepatide, which were mass-produced and sold widely despite not being FDA-approved products.
The FDA Drug Shortage Exception — and Its End
Federal law allows compounding pharmacies to prepare copies of FDA-approved drugs when those drugs are on the FDA’s official drug shortage list. During 2022–2024, both semaglutide and tirzepatide were listed on the shortage list due to genuine supply-demand imbalances. This legally permitted compounding pharmacies to produce these medications during the shortage period.
However, in 2024, the FDA removed semaglutide from the drug shortage list, followed subsequently by tirzepatide. Once a drug is removed from the shortage list, the legal basis for large-scale compounding ceases. The FDA subsequently issued enforcement actions and warning letters to compounding pharmacies that continued to produce these medications after removal from the shortage list. The FDA stated clearly that compounded semaglutide and tirzepatide are not FDA-approved and are not verified for safety, efficacy, or quality.
💡 💡 Clinical Pearl: Semaglutide Salt vs. Semaglutide Base
Many compounding pharmacies used semaglutide sodium or semaglutide acetate (salt forms of semaglutide) rather than the pharmaceutical-grade semaglutide base used in FDA-approved products. The FDA has noted that these salt forms are NOT the same as FDA-approved semaglutide and have not been shown to be bioequivalent or equally safe. The pharmacological activity of these salt forms when injected subcutaneously is unproven and potentially different from approved formulations.
Specific Quality and Safety Risks
Compounded GLP-1 RA products carry a range of serious and documented risks:
- Dosing errors — including 10-fold errors: The FDA and Wharton et al. (2023) documented cases of serious dosing errors with compounded semaglutide, including patients receiving 10 times the intended dose. This occurred due to unclear labeling, non-standardized concentration formulations, and patient confusion about reconstitution of lyophilized (freeze-dried) powder products. Overdose symptoms include severe vomiting, hypoglycemia, aspiration, and cardiovascular compromise.
- Contamination risk: FDA inspections of compounding facilities producing GLP-1 RA found numerous violations including non-sterile conditions, inadequate quality control testing, improper storage, and use of unverified active pharmaceutical ingredients of uncertain purity. Contaminated injectable products can cause serious infections including sepsis.
- Unverified ingredients: Some compounded formulations contained additional, undisclosed additives such as vitamin B12, L-carnitine, or other compounds, for which safety in this context is unestablished. Patients were often not informed of these additions.
- Incorrect storage and stability: FDA-approved semaglutide pens are engineered for specific cold-chain storage and stability profiles. Compounded preparations may not maintain drug stability equivalently, resulting in degraded or inactive product — meaning patients inject an ineffective substance.
- No pharmacovigilance oversight: Adverse events from compounded products are not systematically tracked or reported to the FDA in the same way as approved drug adverse events. Patients harmed by compounded GLP-1 RA have limited legal and regulatory recourse.
The Scale of the Problem
The FDA received hundreds of adverse event reports related to compounded semaglutide, including hospitalizations from severe nausea/vomiting, hypoglycemic episodes, and serious infections. A 2023 analysis by Wharton et al. in the journal Obesity highlighted both the safety concerns and the regulatory challenges posed by the proliferation of compounded GLP-1 RA products, noting the particular danger of 10-fold concentration errors when patients self-inject from multi-dose vials without standardized dosing guides.
How to Protect Yourself
Patients seeking GLP-1 RA therapy should take the following precautions:
- Only use FDA-approved medications: Wegovy, Ozempic, Zepbound, and Mounjaro are the FDA-approved GLP-1 RA products available in the United States. Rybelsus is the approved oral semaglutide. Any other form is not FDA-approved.
- Obtain medications through licensed pharmacies: Use established, brick-and-mortar pharmacies or verified mail-order pharmacies that dispense FDA-approved branded products only.
- Be skeptical of dramatically lower prices: A legitimate Wegovy or Zepbound prescription through standard channels costs $1,000+/month without assistance. Dramatically lower prices often signal compounded or counterfeit products.
- Use manufacturer savings programs: Both Novo Nordisk and Eli Lilly offer legitimate patient assistance programs (see GLP-1 RA Cost and Affordability) that can reduce out-of-pocket costs to $25–99/month for eligible patients.
- Report adverse events: If you believe you have been harmed by a compounded GLP-1 RA, report to the FDA’s MedWatch system (1-800-FDA-1088) and contact your healthcare provider immediately.
💡 Frequently Asked Questions (FAQ)
Q1: Are all compounded medications dangerous?
A1: No — pharmaceutical compounding for legitimate, individualized medical needs is a valuable practice. The danger arises when compounding is used to mass-produce unapproved copies of FDA-approved drugs, bypassing quality, safety, and efficacy oversight. The large-scale production of compounded semaglutide and tirzepatide falls into this problematic category.
Q2: How can I tell if my GLP-1 RA is authentic and FDA-approved?
A2: FDA-approved GLP-1 RA come in branded, pre-filled auto-injector pens (Wegovy, Ozempic, Zepbound, Mounjaro) with standardized dosing, manufacturer labeling, and anti-counterfeiting features. Compounded products typically come in multi-dose vials requiring syringe self-measurement. If you are self-measuring doses from a vial, you are likely using a compounded product.
Q3: Is it legal to buy compounded semaglutide now that it’s off the shortage list?
A3: Following the FDA’s removal of semaglutide from the shortage list in 2024, large-scale compounding of semaglutide is no longer legally permitted under the shortage exception. The FDA has begun enforcement actions against pharmacies continuing to compound these medications. Individual patients should consult with their healthcare provider and use only FDA-approved products.
📚 References & Sources
- Wharton, S., et al. (2023). Compounded semaglutide: safety concerns. Obesity, 31(8), 1978–1980.
- FDA. (2024). FDA alerts patients and health care professionals about risks of compounded GLP-1 medications. FDA Drug Safety Communication. U.S. Food and Drug Administration.
- FDA. (2024). FDA takes action to protect patients from potentially dangerous compounded drugs that copy FDA-approved GLP-1 receptor agonist drugs. FDA News Release.